ClinicalTrials.gg

Program

QL0911

A development code.

Its studies are mostly in Thrombocytopenia · Purpura, Thrombocytopenic, Idiopathic, led by Qilu Pharmaceutical.

Furthest: phase 3, since Sep 18, 20225 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical52 open or runningphase 3since Sep 18, 2022Sep 18, 2022Apr 30, 2027phase 3 · NCT06456528

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2022First study: phase 3 study in Chemotherapy-induced ThrombocytopeniaFirst studyNCT05554913 · 63 enrolled · China
  2. Nov 10, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05621330 · 216 enrolled · China
  3. Apr 23, 2023Phase 3 study in Chemotherapy-induced ThrombocytopeniaNCT05851027 · 50 enrolled · China
  4. Jun 7, 2024Phase 3 study in Cancer Treatment-Induced ThrombocytopeniaNCT06456528 · 235 planned · China
  5. Mar 2, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07455006 · 60 planned

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in Cancer Treatment-Induced ThrombocytopeniaNCT06456528
  2. Dec 10, 2027Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07455006

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07455006Purpura, Thrombocytopenic, Idiopathic3Not yet recruitingDec 10, 202760
NCT06456528Cancer Treatment-Induced Thrombocytopenia · China3RecruitingApr 30, 2027235
NCT05851027Chemotherapy-induced Thrombocytopenia · China3CompletedSep 10, 202150
NCT05621330Purpura, Thrombocytopenic, Idiopathic · China3CompletedDec 13, 2021216
NCT05554913Chemotherapy-induced Thrombocytopenia · China3CompletedFeb 20, 202463

How it is read

Names in the registry

  • “QL0911”, 5 entries

Codes read as this program: QL0911.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.